<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169009</url>
  </required_header>
  <id_info>
    <org_study_id>18-0580</org_study_id>
    <secondary_id>1U01AI141919-01</secondary_id>
    <nct_id>NCT04169009</nct_id>
  </id_info>
  <brief_title>Persistence of Protection by Shingrix</brief_title>
  <official_title>Persistence of Protection Conferred by Shingrix Against Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully&#xD;
      prevents shingles in older people. Two vaccines are currently approved by the Food and Drug&#xD;
      Administration (FDA) to prevent shingles. Zostavax is a live virus vaccine which has been&#xD;
      available since 2006 and prevents shingles about 50% of the time, though it is less effective&#xD;
      the older a person is when they receive it. Shingrix, which was approved by the FDA in 2017,&#xD;
      is not a live virus, but has an additive in the vaccine to boost immune response. It is about&#xD;
      97% effective at preventing shingles regardless of a person's age and so far has been&#xD;
      effective for at least 4 years after vaccination. Because Zostavax has live virus in it,&#xD;
      giving a &quot;challenge&quot; dose of Zostavax - vOka varicella zoster virus - to people who have&#xD;
      received both vaccines (Zostavax or Shingrix) in the past, will allow researchers to learn&#xD;
      more about how the body works to prevent shingles and how any shingles vaccination helps&#xD;
      protect against shingles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of Varicella-Zoster Virus (VZV) DNAemia</measure>
    <time_frame>Until VZV DNA is undetectable in the blood, measured up to Day 7</time_frame>
    <description>Varicella-Zoster Virus (VZV) DNAemia will be measured by polymerase chain reaction (PCR) as a surrogate for viremia over the first 7 days after vOka intradermal (ID) challenge. The outcome measure will be the area under the concentration time curve of the VZV DNAemia expressed in DNA copies/ml of blood.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>ZVL &gt;5 years previously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZVL 6-12 months previously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No previous ZVL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRX &gt;5 years previously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>Intradermal injection of Zostavax</description>
    <arm_group_label>No previous ZVL</arm_group_label>
    <arm_group_label>SRX &gt;5 years previously</arm_group_label>
    <arm_group_label>ZVL 6-12 months previously</arm_group_label>
    <arm_group_label>ZVL &gt;5 years previously</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shingrix</intervention_name>
    <description>Given to subjects in Arm 4 who've never had a herpes zoster vaccine</description>
    <arm_group_label>No previous ZVL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 55-89&#xD;
&#xD;
          -  General good health&#xD;
&#xD;
          -  Women of non-childbearing potential must be postmenopausal or have undergone&#xD;
             hysterectomy or bilateral oophorectomy&#xD;
&#xD;
          -  ARM 1 ONLY: Documented evidence of immunization with ZVL or SRX at least 5 years&#xD;
             previously&#xD;
&#xD;
          -  ARM 2 ONLY; Documented evidence of immunization with ZVL 6-12 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  ARM 3 ONLY: Have never received any shingles vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of herpes zoster (HZ)&#xD;
&#xD;
          -  Blood products received in the 3 months prior to study enrollment or planned for the&#xD;
             subsequent week for Arm 1; Arm 2 requires same exclusion; Arm 3 extends the exclusion&#xD;
             to the week after the vOka challenge, which is 6 months after completing SRX&#xD;
             administration.&#xD;
&#xD;
          -  Significant immune suppressive illness or therapy&#xD;
&#xD;
          -  Concomitant vaccine received within 2 (inactive) or 4 (live) weeks prior to the study&#xD;
             or during the first week of the study.&#xD;
&#xD;
          -  Women of childbearing potential.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Participation in a concurrent clinical study in which the subject will be exposed to&#xD;
             and investigational product during the period starting 7 days before the first dose of&#xD;
             study vaccine through the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Weinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Lang, BSN</last_name>
    <phone>303/724-2454</phone>
    <email>nancy.lang@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana Weinberg, MD</last_name>
    <phone>303-724-4480</phone>
    <email>adriana.weinberg@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trials Center at University of Colorado Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lang, BSN</last_name>
      <phone>303-724-2454</phone>
      <email>nancy.lang@cuanschutz.edy</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Weinberg</last_name>
      <phone>3037244480</phone>
      <email>adriana.weinberg@cuanschutz.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

